Open Label Study of QRX003 Lotion in Participants with Netherton Syndrome added to SSC therapy

• Research type

  Research Study

• Full title

  A Multicenter, Open-Label Study of QRX003 Lotion in Participants with Netherton Syndrome when added to Systemic Standard of Care Therapy

• IRAS ID

  1013472

• Contact name

  Michael Myers

• Contact email

  mmyers@quoinpharma.com

• Sponsor organisation

  Quoin Therapeutics (Ireland) Limited

• Research summary

  The study will assess safety, tolerability and efficacy of a novel Investigational Medicinal Product (IMP) QRX003 (dipalmitoyl hydroxyproline) skin lotion in participants with Netherton Syndrome, when added to the systemic standard of care treatment regimen. The QRX003 lotion 4% will be applied twice daily (BID).
  The patients will have 12 weeks treatment. If they enter the long-term extension study that is being planned, they will exit at week 12; if not, they will attend during 4 more weeks. The study will recruit 16 participants of age 4 years and older.
  Participants will require to complete 5 study visits; Screening, Baseline, Week 6, Week 12 / End of Treatment, and Week 16 / End of
  Study.

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  26/LO/0061

• Date of REC Opinion

  2 Feb 2026

• REC opinion

  Further Information Favourable Opinion